Our UK and global partnerships

Alzheimer’s Research UK is a partner in a number of consortia and other research initiatives, both within the UK and internationally, which aim to accelerate progress in dementia research.

Here you can find more information about our partnerships, some of which provide experimental resources and bespoke funding calls.

UK Partnerships

Brains for Dementia Research

Brains for Dementia Research (BDR) is a joint initiative between Alzheimer’s Research UK and Alzheimer’s Society, in association with the Medical Research Council, which aims to provide high quality human brain tissue to the dementia research community You can find out more about BDR on Researcher Resources.

Join Dementia Research

The aim of Join Dementia Research, established by the National Institute of Health and Clinical Research with support from Alzheimer’s Research UK and Alzheimer’s Society, is to improve the timeliness of study recruitment for researchers, and provide a service to thousands of potential volunteers who want to be involved in research. You can find out more about Join Dementia Research on our Researcher Resources page.

CRACK IT –UnTangle

We are partners in the National Centre for the Replacement, Refinement and Reduction of Animals in Research’s CRACK IT UnTangle challenge. We are currently supporting a £900k collaborative grant to use stem cell models for drug discovery.

Stevenage Bioscience Catalyst Open Innovation Challenge in Neurodegenerative Disease

Alzheimer’s Research UK is a funding partner in a unique open innovation scheme to kick-start biomarker identification and neuroinflammatory research.

Lewy Body Society (UK)

Dr Jay Amin at the University of Southampton has been awarded £213,317.40 over three years to investigate the role of the immune system in dementia with Lewy bodies. This research was supported through an Alzheimer’s Research UK Clinical Research Fellowship with funding from the Lewy Body Society.

Chief Scientist Office (Scotland)

With support from the Scottish Government, we awarded Tara Spires-Jones a Chief Scientist Office Fellowship.

Global partnerships

International Alzheimer’s Disease Research Funder Consortium

We are co-leads of the International Alzheimer’s Disease Research Funder Consortium, alongside the National Institute for Aging and the Alzheimer’s Association. The IADRFC consists of over 20 dementia research funding bodies from around the world, who come together to identify areas of common interest and gaps in knowledge and innovation, so that these can be bridged through collaboration.

Dementia Consortium

We are founding members of the Dementia Consortium, a £3million global partnership between ARUK, Medical Research Council Technology and the pharmaceutical companies, Eisai and Lilly. The aim is to close the gap between academic research and the pharmaceutical industry’s drug-discovery pipeline. Researchers looking to validate promising new targets and progress them into drug discovery research should direct applications to the Dementia Consortium.

MCDN and BAND2

We are partners, along with the Alzheimer’s Association and The Weston Brain Institute, in a global call for research into mechanisms of cellular death in neurodegeneration (MCDN, formerly known as MEND). Applications for this call have now closed.

We are also joint partners with the Alzheimer’s Association, the Michael J. Fox Foundation and the Weston Brain Institute, in a global funding call to stimulate analyses, development and standardisation of Biomarkers Across Neurodegenerative Diseases (BAND2). Applications for this call have now closed.

Canadian Consortium on Neurodegeneration in Aging (CCNA)

Alzheimer’s Research UK is one of the international partners of the CCNA, a large collaborative research initiative, which aims to prevent and mitigate the toll of dementia and related neurodegenerative diseases of ageing.

Coalition Against Major Diseases (CAMD)

The CAMD brings together funding bodies, pharmaceutical companies, academics and drug regulators with one core goal: to accelerate clinical trials for neurodegenerative diseases, starting with Alzheimer’s and Parkinson’s. Our involvement in this initiative will ensure that our interests as a funding body and our expertise in dementia drug discovery are represented in the international forum.

Neuro-MAP

We are partners along with several other charities and funding bodies in the Neurodegeneration Medicines Acceleration Programme (Neuro-MAP), a scheme which aims to identify promising drug projects no longer in development and help scientists to take them forward to the next stage.

SAGE DREAM #1 Challenge

In collaboration with SAGE Bionetworks and other partners, Alzheimer’s Research UK has supported the Alzheimer’s Big Data DREAM Challenge #1. The challenge applied an open science approach to identify AD biomarkers that can be used by the scientific, industrial and regulatory communities to improve AD diagnosis and treatment.